Quick Answer
Prime Medicine, Inc. reported R&D Expense of $160.64 million for fiscal year 2025.
Prime Medicine, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $160.64M | +3.4% |
| 2024 | $155.29M | +5.0% |
| 2023 | $147.91M | +70.5% |
| 2022 | $86.72M | +22.9% |
| 2021 | $70.55M | +2267.4% |
| 2020 | $2.98M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $43.99M | +9.0% | +6.3% |
| June 30, 2025 | $41.38M | -3.9% | +2.0% |
| March 31, 2025 | $40.56M | +7.4% | +0.6% |
| September 30, 2024 | $40.34M | -1.5% | -6.3% |
| June 30, 2024 | $43.07M | +24.5% | +14.0% |
| March 31, 2024 | $37.77M | +22.3% | -7.8% |
| September 30, 2023 | $40.97M | +63.6% | +18.4% |
| June 30, 2023 | $34.60M | — | +12.0% |
- Prime Medicine, Inc. showed an increase of +3.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Prime Medicine, Inc.’s r&d expense has grown by 5290.5% (from $2.98 million to $160.64 million).
- The most recent figure is from Prime Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: